Desperate breast cancer patients get access to promising drug through special program
NCT ID NCT05038631
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This program offers ribociclib, a targeted cancer drug, to patients with serious or life-threatening breast cancer who have no other treatment options and cannot join a clinical trial. Doctors must request the drug for their patients. The goal is to provide potential benefit when standard therapies are exhausted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ribociclib (a targeted cancer drug)
What this could lead to
If successful, this program could provide a treatment option for breast cancer patients who have run out of standard therapies.
What could go wrong
This is not a clinical trial testing a new treatment; it's an access program. Benefits and risks are not systematically studied, and individual results may vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact